Targeted toxins for glioblastoma multiforme: Pre-clinical studies and clinical implementation

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 729-738

  Candolfi, Marianela ^a,b,d   Kroeger, Kurt M ^a,b   Xiong, Weidong ^a,b   Liu, Chunyan ^a,b   Puntel, Mariana ^a,b   Yagiz, Kader ^a,b   Muhammad, Akm Ghulam ^a,b   Mineharu, Yohei ^a,b   Foulad, David ^a,b   Wibowo, Mia ^a,b   Assi, Hikmat ^a,b   Baker, Gregory J ^a,b   Lowenstein, Pedro R ^a,b,c   Castro, Maria G ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Diphtheria toxin; EGFR; EGFRvIII; Gene therapy; IL 13; IL 13r 2; Pseudomonas exotoxin; Targeted toxins; TGF ; Transferrin receptor

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CINTREDEKIN BESUDOTOX; CRM 107; DIPHTHERIA TOXIN EPIDERMAL GROWTH FACTOR FUSION PROTEIN; DIPTHERIA TOXIN UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR FUSION PROTEIN; EPHRIN A1; EPHRIN A1 PE38QQR FUSION PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PSEUDOMONAS EXOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE 14E1 PSEUDOMONAS EXOTOXIN A FUSION PROTEIN; TRANSFERRIN DIPHTHERIA TOXIN MUTANT CRM 107 FUSION PROTEIN; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA PSEUDOMONAS EXOTOXIN 38 FUSION PROTEIN; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BINDING SITE; BRAIN EDEMA; BRAIN INJURY; CELL DEATH; CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; HEMIPARESIS; HISTOPATHOLOGY; HUMAN; MAXIMUM TOLERATED DOSE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN SYNTHESIS; REVIEW; SEIZURE; TUMOR VOLUME;

EID: 80053555147     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378689     Document Type: Review

References (97)

1. Candolfi, M.; Curtin, J. F.; Nichols, W. S.; Muhammad, A. G.; King, G. D.; Pluhar, G. E.; McNiel, E. A.; Ohlfest, J. R.; Freese, A. B.; Moore, P. F.; Lerner, J.; Lowenstein, P. R.; Castro, M. G.; Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J. Neurooncol., 2007, 85, (2), 133-148.
2. Wallner, K. E.; Galicich, J. H.; Krol, G.; Arbit, E.; Malkin, M. G.; Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys., 1989, 16, (6), 1405-1409.
3. Debinski, W.; Gibo, D. M.; Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/ testis antigen. Mol. Med., 2000, 6, (5), 440-449.
4. Debinski, W.; Obiri, N. I.; Pastan, I.; Puri, R. K.; A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem., 1995, 270, (28), 16775-16780.
5. Debinski, W.; Thompson, J. P.; Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas. Clin. Cancer Res., 1999, 5, (10 Suppl), 3143s-3147s.
6. Joshi, B. H.; Leland, P.; Asher, A.; Prayson, R. A.; Varricchio, F.; Puri, R. K.; In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res., 2001, 61, (22), 8058-8061.
7. Liu, T. F.; Willingham, M. C.; Tatter, S. B.; Cohen, K. A.; Lowe, A. C.; Thorburn, A.; Frankel, A. E.; Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug. Chem., 2003, 14, (6), 1107-1114.
8. Puri, R. K.; Leland, P.; Kreitman, R. J.; Pastan, I.; Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int. J. Cancer, 1994, 58, (4), 574-581.
9. Wykosky, J.; Gibo, D. M.; Stanton, C.; Debinski, W.; Interleukin- 13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer Res., 2008, 14, (1), 199-208.
10. Liu, T. F.; Hall, P. D.; Cohen, K. A.; Willingham, M. C.; Cai, J.; Thorburn, A.; Frankel, A. E.; Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin. Cancer Res., 2005, 11, (1), 329-334.
11. Liu, T. F.; Tatter, S. B.; Willingham, M. C.; Yang, M.; Hu, J. J.; Frankel, A. E.; Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol. Cancer Ther., 2003, 2, (8), 783-787.
12. Phillips, P. C.; Levow, C.; Catterall, M.; Colvin, O. M.; Pastan, I.; Brem, H.; Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res., 1994, 54, (4), 1008-1015.
13. Hatanpaa, K. J.; Burma, S.; Zhao, D.; Habib, A. A.; Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia, 2010, 12, (9), 675-684.
14. Mazzoleni, S.; Politi, L. S.; Pala, M.; Cominelli, M.; Franzin, A.; Sergi Sergi, L.; Falini, A.; De Palma, M.; Bulfone, A.; Poliani, P. L.; Galli, R.; Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells inhuman glioblastoma multiforme and is required for gliomagenesis. Cancer Res., 2010, 70, (19), 7500-7513.
15. Wykosky, J.; Gibo, D. M.; Stanton, C.; Debinski, W.; EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res., 2005, 3, (10), 541-551.
16. Sutmuller, R. P.; van Duivenvoorde, L. M.; van Elsas, A.; Schumacher, T. N.; Wildenberg, M. E.; Allison, J. P.; Toes, R. E.; Offringa, R.; Melief, C. J.; Synergism of cytotoxic T lymphocyteassociated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med., 2001, 194, (6), 823-832.
17. Wykosky, J.; Debinski, W.; The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res., 2008, 6, (12), 1795-1806.
18. Mori, T.; Abe, T.; Wakabayashi, Y.; Hikawa, T.; Matsuo, K.; Yamada, Y.; Kuwano, M.; Hori, S.; Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J. Neurooncol., 2000, 46, (2), 115-123.
19. Hall, W. A.; Godal, A.; Juell, S.; Fodstad, O.; In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J. Neurosurg., 1992, 76, (5), 838-844.
20. Martell, L. A.; Agrawal, A.; Ross, D. A.; Muraszko, K. M.; Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res., 1993, 53, (6), 1348-1353.
21. Jarboe, J. S.; Johnson, K. R.; Choi, Y.; Lonser, R. R.; Park, J. K.; Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res., 2007, 67, (17), 7983-7986.
22. Obiri, N. I.; Leland, P.; Murata, T.; Debinski, W.; Puri, R. K.; The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol., 1997, 158, (2), 756-764.
23. Hershey, G. K.; IL-13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol., 2003, 111, (4), 677-690; quiz 691.
24. Debinski, W.; Miner, R.; Leland, P.; Obiri, N. I.; Puri, R. K.; Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem., 1996, 271, (37), 22428-22433.
25. Debinski, W.; Slagle, B.; Gibo, D. M.; Powers, S. K.; Gillespie, G. Y.; Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J. Neurooncol., 2000, 48, (2), 103-111.
26. Debinski, W.; Gibo, D. M.; Hulet, S. W.; Connor, J. R.; Gillespie, G. Y.; Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res., 1999, 5, (5), 985-990.
27. Mintz, A.; Gibo, D. M.; Slagle-Webb, B.; Christensen, N. D.; Debinski, W.; IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia, 2002, 4, (5), 388-399.
28. Ekstrand, A. J.; James, C. D.; Cavenee, W. K.; Seliger, B.; Pettersson, R. F.; Collins, V. P.; Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res., 1991, 51, (8), 2164-2172.
29. Heimberger, A. B.; Hlatky, R.; Suki, D.; Yang, D.; Weinberg, J.; Gilbert, M.; Sawaya, R.; Aldape, K.; Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res., 2005, 11, (4), 1462-1466.
30. Shinojima, N.; Tada, K.; Shiraishi, S.; Kamiryo, T.; Kochi, M.; Nakamura, H.; Makino, K.; Saya, H.; Hirano, H.; Kuratsu, J.; Oka, K.; Ishimaru, Y.; Ushio, Y.; Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res., 2003, 63, (20), 6962-6970.
31. Gan, H. K.; Kaye, A. H.; Luwor, R. B.; The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci., 2009, 16, (6), 748-754.
32. Recht, L.; Torres, C. O.; Smith, T. W.; Raso, V.; Griffin, T. W.; Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg., 1990, 72, (6), 941-945.
33. Calzolari, A.; Larocca, L. M.; Deaglio, S.; Finisguerra, V.; Boe, A.; Raggi, C.; Ricci-Vitani, L.; Pierconti, F.; Malavasi, F.; De Maria, R.; Testa, U.; Pallini, R.; Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl. Oncol., 2010, 3, (2), 123-134.
34. Hill, J. M.; Ruff, M. R.; Weber, R. J.; Pert, C. B.; Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc. Natl. Acad. Sci. USA, 1985, 82, (13), 4553-4557.
35. Connor, J. R.; Fine, R. E.; The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res, 1986, 368, (2), 319-328.
36. Jefferies, W. A.; Brandon, M. R.; Hunt, S. V.; Williams, A. F.; Gatter, K. C.; Mason, D. Y.; Transferrin receptor on endothelium of brain capillaries. Nature, 1984, 312, (5990), 162-163.
37. Lin, L. N.; Mason, A. B.; Woodworth, R. C.; Brandts, J. F.; Calorimetric studies of the binding of ferric ions to human serum transferrin. Biochemistry, 1993, 32, (36), 9398-406.
38. Rao, J. S.; Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 2003, 3, (7), 489-501.
39. Zhang, X.; Fei, Z.; Bu, X.; Zhen, H.; Zhang, Z.; Gu, J.; Chen, Y.; Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J. Surg. Oncol., 2000, 74, (2), 90-94.
40. Hasegawa, Y.; Kinoh, H.; Iwadate, Y.; Onimaru, M.; Ueda, Y.; Harada, Y.; Saito, S.; Furuya, A.; Saegusa, T.; Morodomi, Y.; Hasegawa, M.; Saito, S.; Aoki, I.; Saeki, N.; Yonemitsu, Y.; Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferonbeta gene. Mol. Ther., 18, (10), 1778-1786.
41. Prager, G. W.; Breuss, J. M.; Steurer, S.; Mihaly, J.; Binder, B. R.; Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood, 2004, 103, (3), 955-962.
42. Tsai, A. K.; Oh, S.; Chen, H.; Shu, Y.; Ohlfest, J. R.; Vallera, D. A.; A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J. Neurooncol., 2011, 103(2), 255-266.
43. Li, C.; Hall, W. A.; Jin, N.; Todhunter, D. A.; Panoskaltsis-Mortari, A.; Vallera, D. A.; Targeting glioblastoma multiforme with an IL- 13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng., 2002, 15, (5), 419-427.
44. Todhunter, D. A.; Hall, W. A.; Rustamzadeh, E.; Shu, Y.; Doumbia, S. O.; Vallera, D. A.; A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng. Des. Sel., 2004, 17, (2), 157-164.
45. Pastan, I.; Chaudhary, V.; FitzGerald, D. J.; Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem., 1992, 61, 331-354.
46. Debinski, W.; Pastan, I.; An immunotoxin with increased activity and homogeneity produced by reducing the number of lysine residues in recombinant Pseudomonas exotoxin. Bioconjug. Chem., 1994, 5, (1), 40-46.
47. Puri, R. K.; Leland, P.; Obiri, N. I.; Husain, S. R.; Kreitman, R. J.; Haas, G. P.; Pastan, I.; Debinski, W.; Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood, 1996, 87, (10), 4333-4339.
48. Husain, S. R.; Joshi, B. H.; Puri, R. K.; Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer, 2001, 92, (2), 168-175.
49. Husain, S. R.; Obiri, N. I.; Gill, P.; Zheng, T.; Pastan, I.; Debinski, W.; Puri, R. K.; Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res., 1997, 3, (2), 151-156.
50. Candolfi, M.; Xiong, W.; Yagiz, K.; Liu, C.; Muhammad, A. K.; Puntel, M.; Foulad, D.; Zadmehr, A.; Ahlzadeh, G. E.; Kroeger, K. M.; Tesarfreund, M.; Lee, S.; Debinski, W.; Sareen, D.; Svendsen, C. N.; Rodriguez, R.; Lowenstein, P. R.; Castro, M. G.; Gene therapymediated delivery of targeted cytotoxins for glioma therapeutics. Proc. Natl. Acad. Sci. USA., 2010, 107, (46), 20021-20026.
51. Kawakami, K.; Kawakami, M.; Kioi, M.; Husain, S. R.; Puri, R. K.; Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J. Neurosurg., 2004, 101, (6), 1004-1011.
52. Debinski, W.; Obiri, N. I.; Powers, S. K.; Pastan, I.; Puri, R. K.; Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res., 1995, 1, (11), 1253-1258.
53. Laske, D. W.; Youle, R. J.; Oldfield, E. H.; Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat. Med., 1997, 3, (12), 1362-1368.
54. Mintz, A.; Gibo, D. M.; Madhankumar, A. B.; Debinski, W.; Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J. Neurooncol., 2003, 64, (1-2), 117-123.
55. Sampson, J. H.; Archer, G.; Pedain, C.; Wembacher-Schroder, E.; Westphal, M.; Kunwar, S.; Vogelbaum, M. A.; Coan, A.; Herndon, J. E.; Raghavan, R.; Brady, M. L.; Reardon, D. A.; Friedman, A. H.; Friedman, H. S.; Rodriguez-Ponce, M. I.; Chang, S. M.; Mittermeyer, S.; Croteau, D.; Puri, R. K.; Poor drug distribution as a possible explanation for the results of the PRECISE trial. J. Neurosurg., 2010, 113, (2), 301-309.
56. Kunwar, S.; Prados, M. D.; Chang, S. M.; Berger, M. S.; Lang, F. F.; Piepmeier, J. M.; Sampson, J. H.; Ram, Z.; Gutin, P. H.; Gibbons, R. D.; Aldape, K. D.; Croteau, D. J.; Sherman, J. W.; Puri, R. K.; Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol., 2007, 25, (7), 837-844.
57. Kawakami, M.; Kawakami, K.; Takahashi, S.; Abe, M.; Puri, R. K.; Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer, 2004, 101, (5), 1036-1042.
58. Liu, H.; Jacobs, B. S.; Liu, J.; Prayson, R. A.; Estes, M. L.; Barnett, G. H.; Barna, B. P.; Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and lowgrade astrocytoma differ from malignant glioma. Cancer Immunol Immunother, 2000, 49, (6), 319-324.
59. Liu, H.; Prayson, R. A.; Estes, M. L.; Drazba, J. A.; Barnett, G. H.; Bingaman, W.; Liu, J.; Jacobs, B. S.; Barna, B. P.; In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine, 2000, 12, (11), 1656-1661.
60. Parney, I. F.; Kunwar, S.; McDermott, M.; Berger, M.; Prados, M.; Cha, S.; Croteau, D.; Puri, R. K.; Chang, S. M.; Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg., 2005, 102, (2), 267-275.
61. Debinski, W.; Gibo, D. M.; Obiri, N. I.; Kealiher, A.; Puri, R. K.; Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol, 1998, 16, (5), 449-453.
62. Madhankumar, A. B.; Mintz, A.; Debinski, W.; Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia, 2004, 6, (1), 15-22.
63. Xiong, W.; Candolfi, M.; Kroeger, K. M.; Puntel, M.; Mondkar, S.; Larocque, D.; Liu, C.; Curtin, J. F.; Palmer, D.; Ng, P.; Lowenstein, P. R.; Castro, M. G.; Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol. Ther., 2008, 16, (2), 343-351.
64. Xiong, W.; Goverdhana, S.; Sciascia, S. A.; Candolfi, M.; Zirger, J. M.; Barcia, C.; Curtin, J. F.; King, G. D.; Jaita, G.; Liu, C.; Kroeger, K.; Agadjanian, H.; Medina-Kauwe, L.; Palmer, D.; Ng, P.; Lowenstein, P. R.; Castro, M. G.; Regulatable Gutless Adenovirus Vectors Sustain Inducible Transgene Expression in the Brain in the Presence of an Immune Response against Adenoviruses. J. Virol., 2006, 80, (1), 27-37.
65. Paulus, W.; Baur, I.; Oberer, D. M.; Breakefield, X. O.; Reeves, S. A.; Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J Neurosurg, 1997, 87, (1), 89-95.
66. Keyvani, K.; Baur, I.; Paulus, W.; Tetracycline-controlled expression but not toxicity of an attenuated diphtheria toxin mutant. Life Sci, 1999, 64, (19), 1719-1724.
67. Curtin, J. F.; Candolfi, M.; Xiong, W.; Lowenstein, P. R.; Castro, M. G.; Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol. Cancer Ther., 2008, 7, (3), 439-448.
68. Li, Y.; McCadden, J.; Ferrer, F.; Kruszewski, M.; Carducci, M.; Simons, J.; Rodriguez, R.; Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res., 2002, 62, (9), 2576-2582.
69. Morelli, A. E.; Larregina, A. T.; Smith-Arica, J.; Dewey, R. A.; Southgate, T. D.; Ambar, B.; Fontana, A.; Castro, M. G.; Lowenstein, P. R.; Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosisinducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J. Gen. Virol., 1999, 80 (Pt 3), 571-583.
70. Williams, J. C.; Stone, D.; Smith-Arica, J. R.; Morris, I. D.; Lowenstein, P. R.; Castro, M. G.; Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogeninduced pituitary prolactinomas. Mol. Ther., 2001, 4, (6), 593-602.
71. Dewey, R. A.; Morrissey, G.; Cowsill, C. M.; Stone, D.; Bolognani, F.; Dodd, N. J.; Southgate, T. D.; Klatzmann, D.; Lassmann, H.; Castro, M. G.; Lowenstein, P. R.; Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirusmediated gene therapy: implications for clinical trials. Nat. Med., 1999, 5, (11), 1256-1263.
72. Thomas, C. E.; Birkett, D.; Anozie, I.; Castro, M. G.; Lowenstein, P. R.; Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vectormediated transgene expression in the brain. Mol. Ther., 2001, 3, (1), 36-46.
73. Candolfi, M.; Curtin, J. F.; Xiong, W. D.; Kroeger, K. M.; Liu, C.; Rentsendorj, A.; Agadjanian, H.; Medina-Kauwe, L.; Palmer, D.; Ng, P.; Lowenstein, P. R.; Castro, M. G.; Effective High-Capacity Gutless Adenoviral Vectors Mediate Transgene Expression in Human Glioma Cells. Mol. Ther., 2006, 14, (3), 371-381.
74. Candolfi, M.; Pluhar, G. E.; Kroeger, K.; Puntel, M.; Curtin, J.; Barcia, C.; Muhammad, A. K.; Xiong, W.; Liu, C.; Mondkar, S.; Kuoy, W.; Kang, T.; McNeil, E. A.; Freese, A. B.; Ohlfest, J. R.; Moore, P.; Palmer, D.; Ng, P.; Young, J. D.; Lowenstein, P. R.; Castro, M. G.; Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro. Oncol., 2007, 9, (3), 245-258.
75. Candolfi, M.; Kroeger, K. M.; Muhammad, A. K.; Yagiz, K.; Farrokhi, C.; Pechnick, R. N.; Lowenstein, P. R.; Castro, M. G.; Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther, 2009, 9, (5), 409-421.
76. Wykosky, J.; Gibo, D. M.; Debinski, W.; A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol. Cancer Ther., 2007, 6, (12 Pt 1), 3208-3218.
77. Sampson, J. H.; Akabani, G.; Archer, G. E.; Bigner, D. D.; Berger, M. S.; Friedman, A. H.; Friedman, H. S.; Herndon, J. E., 2nd; Kunwar, S.; Marcus, S.; McLendon, R. E.; Paolino, A.; Penne, K.; Provenzale, J.; Quinn, J.; Reardon, D. A.; Rich, J.; Stenzel, T.; Tourt-Uhlig, S.; Wikstrand, C.; Wong, T.; Williams, R.; Yuan, F.; Zalutsky, M. R.; Pastan, I.; Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol., 2003, 65, (1), 27-35.
78. Karpel-Massler, G.; Schmidt, U.; Unterberg, A.; Halatsch, M. E.; Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol. Cancer Res., 2009, 7, (7), 1000-1012.
79. Sampson, J. H.; Akabani, G.; Archer, G. E.; Berger, M. S.; Coleman, R. E.; Friedman, A. H.; Friedman, H. S.; Greer, K.; Herndon, J. E., 2nd; Kunwar, S.; McLendon, R. E.; Paolino, A.; Petry, N. A.; Provenzale, J. M.; Reardon, D. A.; Wong, T. Z.; Zalutsky, M. R.; Pastan, I.; Bigner, D. D.; Intracerebral infusion of an EGFRtargeted toxin in recurrent malignant brain tumors. Neuro. Oncol., 2008, 10, (3), 320-329.
80. Sampson, J. H.; Archer, G. E.; Mitchell, D. A.; Heimberger, A. B.; Bigner, D. D.; Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol., 2008, 20, (5), 267-275.
81. Sampson, J. H.; Reardon, D. A.; Friedman, A. H.; Friedman, H. S.; Coleman, R. E.; McLendon, R. E.; Pastan, I.; Bigner, D. D.; Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion ofthe recombinant targeted toxin TP-38: case study. Neuro. Oncol., 2005, 7, (1), 90-96.
82. Liu, T. F.; Cohen, K. A.; Willingham, M. C.; Tatter, S. B.; Puri, R. K.; Frankel, A. E.; Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. J. Neurooncol., 2003, 65, (1), 77-85.
83. Schmidt, M.; Maurer-Gebhard, M.; Groner, B.; Kohler, G.; Brochmann-Santos, G.; Wels, W.; Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene, 1999, 18, (9), 1711-1721.
84. Schmidt, M.; Reiser, P.; Hills, D.; Gullick, W. J.; Wels, W.; Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin. Int. J. Cancer, 1998, 75, (6), 878-884.
85. Schmidt, M.; Vakalopoulou, E.; Schneider, D. W.; Wels, W.; Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor. Br J Cancer, 1997, 75, (11), 1575-1584.
86. Michaelis, M.; Bliss, J.; Arnold, S. C.; Hinsch, N.; Rothweiler, F.; Deubzer, H. E.; Witt, O.; Langer, K.; Doerr, H. W.; Wels, W. S.; Cinatl, J., Jr.; Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res, 2008, 14, (20), 6531-6537.
87. Johnson, V. G.; Wrobel, C.; Wilson, D.; Zovickian, J.; Greenfield, L.; Oldfield, E. H.; Youle, R.; Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J. Neurosurg., 1989, 70, (2), 240-248.
88. Greenfield, L.; Johnson, V. G.; Youle, R. J.; Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science, 1987, 238, (4826), 536-539.
89. Johnson, V. G.; Wilson, D.; Greenfield, L.; Youle, R. J.; The role of the diphtheria toxin receptor in cytosol translocation. J. Biol. Chem., 1988, 263, (3), 1295-1300.
90. Weaver, M.; Laske, D. W.; Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol., 2003, 65, (1), 3-13.
91. Yoon, D. J.; Kwan, B. H.; Chao, F. C.; Nicolaides, T. P.; Phillips, J. J.; Lam, G. Y.; Mason, A. B.; Weiss, W. A.; Kamei, D. T.; Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res, 2010, 70, (11), 4520-4527.
92. Yoon, D. J.; Chu, D. S.; Ng, C. W.; Pham, E. A.; Mason, A. B.; Hudson, D. M.; Smith, V. C.; MacGillivray, R. T.; Kamei, D. T.; Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J. Control Release., 2009, 133, (3), 178-184.
93. Hall, W. A.; Vallera, D. A.; Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus, 2006, 20, (4), E23.
94. Japsen, B.; NeoPharm drug fails test: cancer therapy bust sends stock into dive. Chicago Tribune, 2006, Sect. Business, 1.
95. Sampson, J. H.; Brady, M. L.; Petry, N. A.; Croteau, D.; Friedman, A. H.; Friedman, H. S.; Wong, T.; Bigner, D. D.; Pastan, I.; Puri, R. K.; Pedain, C.; Intracerebral infusate distribution by convectionenhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery, 2007, 60, (2 Suppl 1), ONS89-98; discussion ONS98-9.
96. Sampson, J. H.; Raghavan, R.; Provenzale, J. M.; Croteau, D.; Reardon, D. A.; Coleman, R. E.; Rodriguez Ponce, I.; Pastan, I.; Puri, R. K.; Pedain, C.; Induction of hyperintense signal on T2- weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol, 2007, 188, (3), 703-709.
97. Kunwar, S.; Chang, S.; Westphal, M.; Vogelbaum, M.; Sampson, J.; Barnett, G.; Shaffrey, M.; Ram, Z.; Piepmeier, J.; Prados, M.; Croteau, D.; Pedain, C.; Leland, P.; Husain, S. R.; Joshi, B. H.; Puri, R. K.; Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro. Oncol., 2010, 12, (8), 871-881.